Patient demographics and characteristics
| Characteristic . | Antiplatelet, n = 134 . | Control, n = 258 . |
|---|---|---|
| Females | 68 (50.7) | 140 (54.3) |
| Age, median (interquartile range), y | 68.3 (62.1-74.8) | 65.9 (59.3-73.0) |
| Primary malignancy | ||
| NSCLC | 98 (73.1) | 192 (74.4) |
| Small cell lung cancer | 13 (9.7) | 26 (10.1) |
| Renal cell carcinoma | 7 (5.2) | 10 (3.9) |
| Melanoma | 6 (4.5) | 12 (4.7) |
| Gastrointestinal | 3 (2.2) | 6 (2.3) |
| Breast | 2 (1.5) | 4 (1.6) |
| Genitourinary | 2 (1.5) | 3 (1.2) |
| Miscellaneous | 3 (2.2) | 5 (1.9) |
| Comorbidities | ||
| Hypertension | 98 (73.1) | 135 (52.3) |
| Chronic kidney disease | 43 (32.1) | 72 (27.9) |
| Coronary artery disease/myocardial infarction | 20 (14.9) | 12 (4.7) |
| Hypercholesterolemia | 34 (25.4) | 39 (15.1) |
| Other arterial or peripheral vascular disease | 8 (6.0) | 8 (3.1) |
| Cerebrovascular disease | 6 (4.5) | 2 (0.8) |
| Atrial fibrillation or flutter | 6 (4.5) | 7 (2.7) |
| Venous thromboembolism | 5 (3.7) | 10 (3.9) |
| Prior ICH | 1 (0.7) | 2 (0.8) |
| Treatment of brain metastasis | ||
| Systemic therapy | 94 (70.1) | 167 (64.7) |
| Stereotactic brain radiation therapy | 70 (52.2) | 120 (46.5) |
| Whole brain radiation | 68 (50.7) | 111 (43.0) |
| Neurosurgery | 39 (29.1) | 90 (34.9) |
| Anticoagulation exposure | 31 (23.1) | 57 (22.1) |
| Enoxaparin | 27 (20.1) | 53 (20.5) |
| Apixaban | 3 (2.2) | 5 (1.9) |
| Rivaroxaban | 3 (2.2) | 1 (0.4) |
| Characteristic . | Antiplatelet, n = 134 . | Control, n = 258 . |
|---|---|---|
| Females | 68 (50.7) | 140 (54.3) |
| Age, median (interquartile range), y | 68.3 (62.1-74.8) | 65.9 (59.3-73.0) |
| Primary malignancy | ||
| NSCLC | 98 (73.1) | 192 (74.4) |
| Small cell lung cancer | 13 (9.7) | 26 (10.1) |
| Renal cell carcinoma | 7 (5.2) | 10 (3.9) |
| Melanoma | 6 (4.5) | 12 (4.7) |
| Gastrointestinal | 3 (2.2) | 6 (2.3) |
| Breast | 2 (1.5) | 4 (1.6) |
| Genitourinary | 2 (1.5) | 3 (1.2) |
| Miscellaneous | 3 (2.2) | 5 (1.9) |
| Comorbidities | ||
| Hypertension | 98 (73.1) | 135 (52.3) |
| Chronic kidney disease | 43 (32.1) | 72 (27.9) |
| Coronary artery disease/myocardial infarction | 20 (14.9) | 12 (4.7) |
| Hypercholesterolemia | 34 (25.4) | 39 (15.1) |
| Other arterial or peripheral vascular disease | 8 (6.0) | 8 (3.1) |
| Cerebrovascular disease | 6 (4.5) | 2 (0.8) |
| Atrial fibrillation or flutter | 6 (4.5) | 7 (2.7) |
| Venous thromboembolism | 5 (3.7) | 10 (3.9) |
| Prior ICH | 1 (0.7) | 2 (0.8) |
| Treatment of brain metastasis | ||
| Systemic therapy | 94 (70.1) | 167 (64.7) |
| Stereotactic brain radiation therapy | 70 (52.2) | 120 (46.5) |
| Whole brain radiation | 68 (50.7) | 111 (43.0) |
| Neurosurgery | 39 (29.1) | 90 (34.9) |
| Anticoagulation exposure | 31 (23.1) | 57 (22.1) |
| Enoxaparin | 27 (20.1) | 53 (20.5) |
| Apixaban | 3 (2.2) | 5 (1.9) |
| Rivaroxaban | 3 (2.2) | 1 (0.4) |
Unless otherwise noted, data are n (%).